Mavrilimumab Biosimilar - Research Grade

Human

GM-CSF

>1mg/ml

Human IgG1-Lambda2

Anti-Mouse GM-CSF (MP1-22E9) In Vivo Antibody - Low Endotoxin (ICH1125), Lenzilumab Biosimilar - Research Grade (ICH5166), Gimsilumab Biosimilar - Research Grade (ICH5574), Namilumab Biosimilar - Research Grade (ICH5697), Otilimab Biosimilar - Research Grade (ICH5748), Plonmarlimab Biosimilar - Research Grade (ICH5777)

https://www.imgt.org/mAb-DB/

ICH3002

P04141

1437

RRID:AB_2921596

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-inflammatory antibody mavrilimumab, supplied strictly for research use only. It is not the clinical drug and is not intended for human or veterinary use. Mavrilimumab is a human IgG antibody that acts on granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling; the well-established originator target is the GM-CSF receptor alpha chain (GM-CSFRalpha / CSF2RA / CD116) rather than the GM-CSF cytokine itself (see flag). The analog is useful as a functional research reagent for probing GM-CSF axis biology in vitro and in preclinical settings: as a binding and neutralization tool, an isotype-matched or pathway-specific control, a benchmarking standard alongside other GM-CSF-axis antibodies, and a starting reagent for assay development, ADCC/effector characterization, and antibody-engineering or biosimilarity workflows. It is offered at research grade with low endotoxin (typically <1 EU/mg, with an ultra-low <0.5 EU/mg option), and is available in bulk milligram-to-gram quantities to support in-vitro standards and larger preclinical studies. No clone identity is implied. Granulocyte-macrophage colony-stimulating factor (GM-CSF, gene CSF2; UniProt P04141) is a monomeric glycoprotein cytokine that drives the survival, proliferation, differentiation, and activation of myeloid cells including granulocytes, monocytes, macrophages, and dendritic cells. It signals through a heterodimeric receptor comprising a ligand-specific alpha subunit (GM-CSFRalpha / CSF2RA / CD116) and a shared beta common subunit (CSF2RB), engaging JAK2-STAT5 as the dominant pathway along with MAPK, PI3K-AKT, and NF-kB signaling. Beyond steady-state hematopoiesis, GM-CSF is a key pro-inflammatory mediator: it licenses tissue macrophages toward inflammatory phenotypes and contributes to the pathology of rheumatoid arthritis, giant-cell arteritis, and other autoimmune and inflammatory conditions, making the GM-CSF/GM-CSFRalpha axis an actively pursued therapeutic target.

Colony-stimulating factor, CSF, Molgramostin, Sargramostim, Granulocyte-macrophage colony-stimulating factor, CSF2

Detects human GM-CSF. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Mavrilimumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Mavrilimumab (anti-GM-CSF) Biosimilar

Q: Is the Mavrilimumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Mavrilimumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Mavrilimumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Mavrilimumab that binds human GM-CSF.